Mefenamic Acid is Safe for Patients with G6PD Deficiency
Mefenamic acid can be used safely in patients with G6PD deficiency, as there is no evidence linking this NSAID to hemolytic anemia in G6PD-deficient individuals.
Evidence-Based Assessment
The FDA drug label for mefenamic acid 1 contains no warnings or contraindications regarding G6PD deficiency. This absence of regulatory concern is significant, as medications with established hemolytic risk in G6PD deficiency (such as dapsone, methylene blue, nitrofurantoin, phenazopyridine, primaquine, rasburicase) carry explicit warnings.
Risk Classification
A comprehensive evidence-based review identified only seven medications with solid evidence for causing hemolysis in G6PD-deficient patients: dapsone, methylene blue, nitrofurantoin, phenazopyridine, primaquine, rasburicase, and toluidine blue 2. Mefenamic acid is not among these high-risk medications.
The 2023 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline systematically classified medications by hemolytic risk in G6PD deficiency 3. This authoritative guideline does not list mefenamic acid as a medication requiring precautions, suggesting it falls into the low-to-no risk category where standard prescribing practices apply.
Real-World Safety Data
A large real-world study of 31,962 G6PD-deficient patients found that only 71 cases (0.2%) experienced major hemolysis requiring hospitalization over 13 years 4. Of these:
- 71.8% were caused by fava beans
- 8.5% by infections
- Only 4.2% potentially medication-related (nitrofurantoin, phenazopyridine, and an unspecified "pain killer")
Notably, NSAIDs like mefenamic acid were not implicated in any hemolytic episodes in this extensive cohort.
Clinical Implications
When to Prescribe
- Use mefenamic acid at standard therapeutic doses for approved indications (dysmenorrhea, pain) in G6PD-deficient patients
- No dose adjustment or special monitoring required based solely on G6PD status
- Standard NSAID precautions apply (renal function, GI risk, cardiovascular risk)
Common Pitfall to Avoid
Do not confuse mefenamic acid with medications that genuinely pose hemolytic risk. The historical tendency to wrongly attribute hemolysis to medications when patients were actually experiencing infection-related hemolytic episodes has led to unnecessarily restrictive medication lists 2.
Monitoring Considerations
While mefenamic acid itself does not require special monitoring for hemolysis in G6PD deficiency, remain vigilant for:
- Concurrent infections (the actual trigger for most hemolytic episodes in G6PD deficiency)
- Co-administration of genuinely high-risk medications
- Standard NSAID-related adverse effects (renal dysfunction, GI bleeding)
The evidence clearly supports that G6PD deficiency should not be a barrier to prescribing mefenamic acid when clinically indicated.